Nintedanib | Placebo | |
Subjects | 723 | 508 |
Higher cardiovascular risk | 656 (90.7) | 451 (88.8) |
With history of atherosclerotic CVD | 143 (19.8) | 102 (20.1) |
Without history of atherosclerotic CVD | 513 (70.9) | 349 (68.7) |
Lower cardiovascular risk | 67 (9.3) | 57 (11.2) |
Data are presented as n or n (%). CVD: cardiovascular disease.